Monoclonal Antibody (mAb) Drugs in Cancer Therapy

Forfattere

  • Dr.DURGADAS GOVIND NAIK Associate Professor International Medical School Management & Science University

Nøgleord:

Monoclonal antibody, cancer therapy, trastuzumab, bevacizumab, rituximab, non-Hodgkin’s lymphoma, colo-rectal cancer

Resumé

Monoclonal antibodies (mAb) are widely used in the diagnosis of diseases, detection of marker molecules and in therapy. The mAb drugs are increasingly used to treat hypersensitivity, autoimmune diseases, transplantation rejection and more importantly in cancer therapy. Although the application of mAbs in the treatment of infectious diseases is limited, the wide acceptance of these drugs in cancer therapy is remarkable. As of 2011, at least 11 FAB approved mAb drugs are being used for cancer treatment. The leading mAb drugs used in cancer therapy include rituximab, trastuzumab, alemtuzumab, ibritumomab, bevacizumab, cetuximab. Avastin (bevacizumab) a broad spectrum mAb used in colon cancer therapy and Rituximab (rituximab) for non-Hodgkin’s lymphoma had sales of more than $6 billion. In 2010, the mAb drug market was worth $44 billion. It is estimated that all medical biotech products including mAb drugs constitute 25% of total pharma market in near future

Downloads

Publiceret

2012-08-23

Nummer

Årg. 2 Nr. 2 (2012)

Sektion

Review Articles

Licens

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

·         I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.

·         I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).

·         I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.

·          I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

_______________

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.